Single dose of Glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses by Arun V Iyer et al.
Iyer et al. Virology Journal 2013, 10:317
http://www.virologyj.com/content/10/1/317RESEARCH Open AccessSingle dose of Glycoprotein K (gK)-deleted HSV-1
live-attenuated virus protects mice against lethal
vaginal challenge with HSV-1 and HSV-2 and
induces lasting T cell memory immune responses
Arun V Iyer1,3†, Bapi Pahar2†, Vladimir N Chouljenko1, Jason D Walker1, Brent Stanfield1
and Konstantin G Kousoulas1*Abstract
Background: Herpes simplex virus type-1(HSV-1) and HSV-2 are important human pathogens that cause significant
ocular and urogenital complications, respectively. We have previously shown that HSV-1 virions lacking glycoprotein
K (gK) are unable to enter into neurons via synaptic axonal membranes and be transported in either retrograde or
anterograde manner. Here, we tested the ability of HSV-1 (F) gK-null to protect against lethal challenge with either
highly virulent ocular HSV-1 (McKrae strain), or genital HSV-2 (G strain). The gK-null virus vaccine efficiently
protected mice against lethal vaginal infection with either HSV-1(McKrae) or HSV-2 (G).
Results: Female mice were immunized via a single intramuscular injection with 106 PFU of the gK-null virus.
Immunized mice were treated with Depo-Provera fourteen days after vaccination and were challenged via the
vaginal route one week later. Ninety percent of mice vaccinated with the gK-null virus survived HSV-1 (McKrae)
challenge, while 70% of these mice survived after HSV-2 (G) challenge. Moreover, all vaccinated mice exhibited
substantially reduced disease symptoms irrespective of HSV-1 or HSV-2 challenge as compared to the mock
vaccinated challenge group. T-cell memory immune responses to specific glycoprotein B (gB) and glycoprotein D
(gD) peptide epitopes were detectable at 7 months post vaccination.
Conclusions: These results suggest that the highly attenuated, non-neurotropic gK-null virus may be used as an
effective vaccine to protect against both virulent HSV-1 and HSV-2 genital infections and induce lasting immune
responses.Introduction
HSV-1 and HSV-2 are closely related viruses sharing 83%
nucleotide homology [1]. However, these viruses cause dif-
ferent spectrum of disease symptoms. HSV-1 is the causa-
tive agent of cold sores, herpetic whitlow, herpes keratitis
and ocular infections [2]. It is also a leading cause of infec-
tious blindness in the United States [3]. HSV-2 however, is
primarily a sexually transmitted disease more often re-
stricted to the genitals [4], although in recent years, HSV-* Correspondence: vtgusk@lsu.edu
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reproduction in any medium, provided the or1 has been increasingly identified with genital herpes in-
fections [5-7]. Both HSV-1 and HSV-2 produce persistent
lifelong infections by establishing latency in immune privi-
leged sensory neurons [8]. Herpes infections can carry sig-
nificant social implications, and the economic costs
associated with genital herpes is substantial (projected to
be around $2.5 billion in 2015 and around $3 billion in
2025) [9].
A number of vaccine approaches and candidates have
been evaluated in laboratory animals and humans, includ-
ing purified peptides, recombinant glycoprotein subunits,
inactivated, live attenuated, replication competent and rep-
lication defective whole viruses among others (reviewed in:
[10-13]). Recently, a clinical trial using the gD subunit vac-
cine produced by GlaxoSmithKline showed that it was. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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but not in preventing HSV-2 disease or infection [14].
Replication competent live attenuated virus vaccines
have the distinct advantage of replicating in the host’s cells
providing a broader spectrum of viral antigens and patho-
gen associated molecular patterns than non-replicating
vaccine approaches. Ideally, a single live attenuated HSV-1
vaccine virus should provide immunogenic determinants
shared by both HSV-1 and 2, conferring cross-protection.
In addition to being attenuated, such a vaccine should
have a high safety profile and not persist i.e., enter latency.
A number of herpes viruses with a variety of genetic dele-
tions have been evaluated as live attenuated vaccines.
These include deletions in glycoprotein E (gE) [15,16],
multiple deletions in γ34.5, UL55-56, UL43.5, US10-12
[17], UL5, UL29, UL42, ICP27 genes [18-21], deletion of
ICP0- [22] and the UL9 genes [23-26].
In this paper, we describe the use of a glycoprotein K-
deleted HSV-1 (gK-null) virus as an effective vaccine to
protect against lethal challenge with HSV-1 and HSV-2.
We have previously shown that gK plays a significant role
in HSV-1 infection of cells and is vital to the cellular spread
of HSV-1 [27-34]. Previous research from our laboratory
indicates that HSV-1 mutants lacking gK are unable to effi-
ciently infect and establish latency in neurons [3]. Appar-
ently, this stems from the inability of gK-null virions to
efficiently infect neurons via synaptic axonal membranes
[35]. As a result, this attenuated virus is an ideal vaccine
candidate; it is safe, while at the same time it is capable of
presenting, with the exception of gK, the full spectrum of
viral antigens and innate immune triggers. Additionally, gK
has been implicated as a viral glycoprotein that enhances
virulence and exacerbates acute ocular disease [36-39], and
its absence is likely to enhance safety.
Here, we report that a single inoculation with the gK-
null virus successfully protects mice against lethal vaginal
challenge with the highly neurovirulent HSV-1 (McKrae),
or HSV-2 (G), reducing both the severity and occurrence
of disease symptoms. The gK-null vaccine protected 90%
of the mice against HSV-1 and 70% of the mice against
HSV-2 lethal infection. Analysis of T-cell responses showed
that the vaccine produced long-term memory T cell re-
sponses to known CD4+ and CD8+ epitopes of HSV-1 gly-
coproteins gB and gD.
Results
HSV-1 and HSV-2 challenge following vaccination with
gK-null
The gK-null virus was constructed by deletion of the gK
gene using double-red recombination in conjunction
with the HSV-1 genome cloned into a bacterial artificial
chromosome (see Materials and Methods) (Figure 1). We
have previously shown that this HSV-1 F gK-null virus has
reduced replication ability in non-complementing Verocells [40]. Upon vaccination, mice were observed daily for
clinical symptoms and adverse reactions to the vaccine.
Vaccinated animals showed no apparent injection site re-
actions (not shown) nor did they present with any disease
symptoms prior to challenge. Following vaginal challenge
with HSV-1 and HSV-2 all animals were observed on a
daily basis for disease manifestation. Clinical scores and
observations were recorded for 14 days post-virus chal-
lenge (Figure 2A). Mock-vaccinated animals challenged
with either HSV-1or HSV-2 exhibited pronounced clinical
signs to various degrees. Disease symptoms in the mildest
cases consisted primarily of hair loss, hunched posture and
fur ruffling. More advanced disease symptoms included va-
ginal and peri-anal erythema and edema, accompanied by
purulent discharge (Figure 2B). The manifestation of symp-
toms was similar between HSV-1 and HSV-2 challenged
mice within each group (not shown).
Mortality was delayed in the vaccinated groups. Within
both the HSV-1 and HSV-2 challenge groups, mock vacci-
nated animals started to die as early as 7 days post chal-
lenge with a majority of deaths occurring on day 9. In
contrast only a single animal died on day 13 in the vacci-
nated groups challenged with HSV-1. Similarly, deaths
among vaccinated animals challenged with HSV-2 occurred
on days 12 and 13. Protection against lethal infection was
significantly higher in the vaccinated group compared with
the control for HSV-1 challenge: 90% vs. 10% (p = 0.0002)
(Figure 3A). Moreover vaccinated animals showed a reduc-
tion in the severity and occurrence of disease symptoms
post-challenge when compared with controls. We observed
similar results in the HSV-2 challenge groups. Seventy per-
cent of the vaccinated animals survived intra-vaginal chal-
lenge with HSV-2, while none of the mock-vaccinated
animals survived the challenge (p = 0.0001). The majority of
deaths occurred on day 9 in the mock group compared
with day 12 in the three vaccinated mice that died after
HSV-2 challenge (Figure 3B). Recently, we have performed
similar experiments with new gK-null-like mutant viruses
that contain portions of gK and have obtained similar clin-
ical symptoms and protection results (data not shown;
Stanfield et. al., manuscript in preparation).
T cell memory responses to HSV-1 targets in
vaccinated animals
To assess the establishment of T cell memory directed
against HSV-1 epitopes, splenocytes from vaccinated and
control mice were collected 7 months post vaccination
and stimulated with purified peptide fragments derived
from major HSV-1 surface antigens gB and gD. Following
ex vivo peptide stimulation, the splenocytes were assessed
for activation of CD4+ and CD8+ T cells using intracellu-
lar IFN-γ and TNF-α as markers of activation. Represen-
tative results and gating strategies from flow cytometry
are -shown in Additional file 1: Figure S1. Peptide
Figure 1 Schematic of the strategy for the construction of pYEbac102 mutant BAC. The top line represents the prototypic arrangement of
the HSV-1 genome, with the unique long (UL) and unique short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions.
Shown below are the expanded genomic regions of the UL53 ORFs as well as the approximate locations of the sites to which insertion of the
marker genes was targeted and the primers used in diagnostic PCR to confirm the presence of each mutation. PCR fragments containing the
GFP-zeocin resistance gene cassette flanked by 50 bp of viral sequences on both sides were used for targeted recombination in E. coli to
construct pYEbac102 mutant BAC with insertion-deletion mutations in the UL53 ORF. The approximate locations of the primers used in
amplification of each PCR fragment are also shown.
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IFN-γ and/or TNF-α positive T cell frequencies above a
baseline established using mock vaccinated mice. IFN-γ re-
sponses were more common in both CD4+ and CD8+ T
cell populations than TNF-α. T cell responses to the gB
(161–176) peptide were most common among the epitopes
tested, and, CD8+ T cell responses were more frequently
observed than CD4+ (Figure 4) with 70% producing antigen
specific CD8+ IFN-γ in response to gB (161–176) peptide
(Figure 4 top right panel).
T cell phenotypes in isolated splenocytes
The overall percentages of CD4 and CD8 T cells in isolated
splenocytes, without ex vivo activation, were determined for
all unvaccinated, HSV-1 vaccinated and HSV-1 vaccinated-
challenged mice. There were no significant differences in
CD4+ and CD8+ T cell population percentages among all
the groups of mice tested (Figure 5, upper row). CD69 sur-
face expression was used as an early activation marker of T
cells to indicate activation status [41]. The mean percent-
ages of CD69 positive CD4+ T cells were 9.6% in vaccinated
mice and 8.8% in mock vaccinated mice and were not sig-
nificantly different. In contrast, a significantly higher propor-
tion of splenic CD8+ T cells were positive for CD69 in the
vaccinated and challenged group of animals when compared
to other groups of mice (p < 0.05) (Figure 5, bottom row).
Profile of regulatory T cell population in vaccinated
versus mock-vaccinated mice
FoxP3 is a classic and specific marker expressed in all CD4+
Treg cells that have regulatory activity. The combination ofthe three markers CD4+, CD25+, FoxP3+ reveals the
presence of activated Tregs that typically dampen the im-
mune response. Reduction of Tregs correlates with in-
creased vaccine efficacy. We examined both total FoxP3+
Treg cells, and CD4 + CD25 + FoxP3+ Treg cells to assess
their dynamics in all mock and vaccinated groups of mice
(see Figure 6A for gating strategy). Total FoxP3 expression
in CD4+ T cells from vaccinated mice compared to the
mock-vaccinated mice, was not significantly different.
Similarly, the CD4 + CD25 + FoxP3+ Treg populations
were not different between mock and HSV- 1 vaccinated
mice (Figure 6B). However, FoxP3+ cells and CD4 +
CD25 + FoxP3+ Treg cells were significantly reduced in
vaccinated-challenged mice compared to vaccinated only
mice (Figure 6).Discussion
We have previously shown that HSV-1 virions lacking
glycoprotein K (gK) are unable to infect neurons and es-
tablish latency [3]. Moreover, gK-null virions are unable
to be transported in either retrograde or anterograde di-
rections in neuronal cell cultures [35]. Here, we show
that a single inoculation of the replication competent
HSV-1 (gK-null) was sufficient to provide a substantial
and significant degree of protection against both virulent
HSV-1 and HSV-2 strains in a murine vaginal challenge
model. Vaccination caused persistent HSV-1/HSV-2-spe-
cific CD4+ and CD8+ T-cell mediated immune responses
to essential viral antigens, which were further enhanced
upon challenge with either HSV-1 or HSV-2 viruses.
Figure 2 Clinical disease score and pathology. (A) Clinical
disease scores for vaccinated and mock vaccinated animals
challenged with HSV-1 (McKrae) or HSV-2(G). Detailed clinical scores
from seven days post challenge was recorded. Scores on a scale of
1–6 were assigned based on the following scheme: 0 = no disease,
1 = ruffled fur and generalized morbidity, 2 = mild genital erythema
and edema, 3 = moderate genital inflammation, 4 = genital
inflammation with purulent discharge, 5 = hind limb paralysis and
6 = death. Animals showing hind limb paralysis were immediately
euthanized and scored as dead from the following day. In both
HSV-1 (McKrae) and HSV-2(G) challenge groups, a significant
difference was observed between mock vaccinated and vaccinated
animals (p = 0.0005) using a two-tailed paired T-test. (B) HSV-1
(McKrae) and HSV-2(G) infected mice exhibited similar disease
progression and pathology. (a) Mock-infected vagina. (b) Mild
disease symptoms included ruffled fur, hunching posture,
inflammation and redness of vagina. (c) More serious
manifestations included purulent vaginal discharge.
Figure 3 Kaplan-Meier survival curves. Vaccinated and mock-
vaccinated mice were challenged thorough the intra-vaginal route
with 106 PFU of HSV-1 McKrae (A) or HSV-2(G) (B) 21 days post
primary vaccination and observed for 14 days. Ninety percent of the
vaccinated animals in the HSV-1 challenged group survived, while
90% of the mock-vaccinated animals died (A). A statistically
significant difference was observed between the vaccinated and
mock-vaccinated groups (p = 0.0002) using the Gehan-Breslow-
Wilcoxin test. Among animals challenged with HSV-2(G), 70% of the
vaccinated group survived while 100% of the mock-vaccinated
animals died (B). A statistically significant difference was observed
between the vaccinated and mock-vaccinated groups (p = 0.0001)
using the Gehan-Breslow-Wilcoxin test.
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HSV-1(F) is substantially less virulent than HSV-1 (McKrae)
via ocular or epithelial routes (unpublished observa-
tions); therefore the HSV-1(F) gK-null virus utilized
here is predicted to be even more defective for neuro-
virulence than a HSV-1(McKrae) gK-null virus. This
conclusion is supported by the observations that intra-
muscular injection of mice with the HSV-1(F) gK-null
did not cause clinical disease symptoms.
Typically, mice are resistant to either HSV-1 or HSV-2
challenge via the genital route. However, systemic pre-
treatment of animals with Depo-Provera has been shown to
increase susceptibly of mice to herpes simplex infections, in
Figure 4 CD4+ and CD8+ T-cell responses to HSV-1 vaccine antigens. Cells were stimulated with either HSV-1 gB or HSV-1 gD peptide
ex vivo for 6 hrs and then stained for the detection of antigen-specific IFN-γ and TNF-α cytokine responses. The responses for each mouse for the
specified antigen are shown in scattered plots. The cutoff value for IFN-γ and TNF-α cytokine responses were based on the data generated from
the mock control mice. Percentages of responses greater than 0.03 are considered positive for the specified antigen and cytokine response.
Media control values were subtracted from each value before the analysis.
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In these vaccination-challenge experiments, mice were vac-
cinated intramuscularly, since this is the most common
route utilized by commercially available human vaccines.
Vaccinated mice were challenged intra-vaginally with viru-
lent HSV-1 (McKrae) and HSV-2 (G) viruses. Both HSV-1
and HSV-2 strains are commonly found in genital herpesinfections, although HSV-1 strains generally appear to
cause milder disease symptoms. Surprisingly, HSV-1
(McKrae) and HSV-2(G) intra-genital infections at the
single dose of 106 PFU produced similar levels of localized
inflammation and overall clinical disease symptoms in
naïve mice. These results showed that HSV-1(McKrae),
originally isolated from a patient with herpes keratitis,
Figure 5 CD4 and CD8 T lymphocyte counts and their activation in mock, vaccinated and vaccinated-challenged mice. No substantial
changes in CD4 and CD8 population were noticed within mock, vaccinated and vaccinated-challenged group of mice. However, there was an
increased CD8 + CD69+ T cell activation monitored in vaccinated-challenged mice compared to other groups (P < 0.05).
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in mice, as it has been reported previously [43].
The observed protection from a single dose is signifi-
cant and subsequent boosts may be expected to enhance
survival rates among challenged mice and further reduce
disease severity.
To assess whether long-term immunity was estab-
lished by the HSV-1(gK-null) vaccine, antigen-specific
cellular immune responses were determined for selected
peptides at approximately 7 months post vaccination.
Vaccinated mice exhibited both gB and gD-specific CD4+
and CD8+ T cell mediated immune responses. In relative
terms, the most prominent T cell response observed was
from gB (161–176) reactive CD8 cells, with 70% of the
mice generating IFN-γ positive cells. In human patients,
this particular T-cell epitope was identified as recalling the
strongest HLA-DR-dependent CD4+ T-cell proliferation
and IFN-γ production [44]. Interestingly, these studies
identified gB (166–180) and gB (666–680) as a strong
CD4+ T cell recall peptides producing cytotoxic T cells
that could lyse autologous HSV-1 and gB expressing lym-
phoblastoid cell lines. These two peptides correlated with
asymptomatic (i.e. protective) immune responses suggest-
ing that they may be better candidates in investigating
anti-gB CD4+ T cell responses than gB (161–176) utilized
in this study [44], provided that these peptides are equallyrecognized by mouse-specific T-cell responses. The gB
(161–176) and gB (166–180) are identical between HSV-1
and HSV-2, therefore, immune responses to these peptides
generated by the HSV-1 vaccine could contribute to
cross-protection against both HSV-1 and HSV-2 infec-
tions. Although the gB (161–176) peptide is known to
elicit CD4+ T cell response, it also elicited CD8+ T cell re-
sponses in our hands. CD8+ T cell epitope prediction al-
gorithms [45] reveal the potential presence of a CD8+ T
cell epitope (TYYKDVTVSQV) within the gB (161–176)
peptide. This peptide could be generated after intracellular
processing of the gB (161–176) peptide and presented by
MHC class I, eliciting CD8+ T cell responses. The two gD
peptides used here are HSV-1 specific; however, they
differ from HSV-2 gD peptides by only one amino acid
each, suggesting that they may also be able to contrib-
ute to CD8+ T-cell specific cross-protection against
HSV-2 infection.
CD69 is an early T-cell activation marker, which is indi-
cative of recent antigenic stimulation of T cells. Typically,
this CD69+ expression subsides as the activated T-cell ma-
tures. However, it is known that acute viral infections can
produce viral antigen depots in secondary lymphoid or-
gans that can persist for months [46]. Therefore, the ob-
served elevation in CD69+ positive T cells may indicate
the presence of either residual HSV-1/HSV-2 antigens, or
Figure 6 Role of regulatory T cells in mock, HSV-vaccinated and HSV-vaccinated-challenged mice. (A) Representative contour plots
showing the gating strategy for total FoxP3 and FoxP3 + CD25+ CD4+ Treg cells from splenocytes of a mock vaccinated mouse. (B & C)
Percentages of total FoxP3 and CD25 + FoxP3+ CD4+ T-reg cells in three different groups of mice. A statistically significant difference (P < 0.05)
was observed between HSV-vaccinated- and challenged as compared to vaccinated mice that were not challenged.
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not cause any appreciable clinical disease symptoms.
FoxP3+ reveals the presence of activated Tregs that typic-
ally dampen the immune response. Thus, the observed
lower levels of these Tregs appear to correlate with en-
hanced protection against the challenge viruses.
Innate and adaptive immune mechanisms are very im-
portant in determining the outcome of an HSV-1/HSV-2
infection. Specifically, production of type I interferon is as-
sociated with protection against disease and enhances acti-
vation of multiple cell types including natural killer (NK)
cells and plasmacytoid dendritic cells (pDCs) thus contrib-
uting to anti-HSV immune responses [47]. Adaptive im-
mune responses are thought to play critical roles in disease
progression, latency and control of HSV spread [47]. Re-
cently, the importance of cellular immunity was furthersupported by the prime pull and boost approach in which
conventional parenteral vaccination was first utilized to
elicit systemic T-cell responses (prime), followed by recruit-
ment of activated T cells by topical chemokine application
to the genital tract (pull). This vaccination approach re-
duced HSV-2 spread into sensory neurons and prevented
development of clinical disease [48].
HSV contains several pathogen-associated molecular
patterns (PAMPs) that trigger toll-like receptor (TLR)
signaling leading to innate immune activation [49]. Sub-
unit and defective herpes virus vaccines are incapable of
presenting the complete range of these stimuli which in-
clude PAMPs that are only present during late stages of
the replication cycle, i.e. double stranded RNA binding
to TLR-3. In addition, all herpes viruses cause virus-
induced cell fusion as well as fusion of the viral envelope
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through the stimulator of interferon genes (STING) [50].
Therefore, a replication competent, but otherwise safe
HSV vaccine strain would provide a broader range of im-
mune stimuli not presented via subunit or virus-like parti-
cles (VLP) vaccines, which may explain the failure of
subunit vaccine to induce satisfactory levels of protection
against HSV.
Generally, live-attenuated viral vaccines mimic natural
infections and induce more robust humoral and cellular
immune responses against a broad spectrum of viral pro-
teins in comparison to subunit vaccines that typically ex-
press a single viral protein. Moreover, adaptive immune
responses are particularly important in conferring protec-
tion against HSV-1 and HSV-2 infections [44,45]. Re-
cently, it was shown that HSV-2-specific CD8+ T cells
generated after chemoattractant therapy given vaginally in
mice mediated long-lived protection against HSV-2 chal-
lenge [46,47]. Our results suggest that immunization with
the gK-null virus induces long-term antigen-specific CD8+
T cell responses. It is possible that gK-null immunization
induces local intravaginal CD8+ T cell responses that con-
tribute to the observed level of protection against HSV-1
or HSV-2 challenge. Furthermore, gK has been associated
with increased virulence and immunopathogenesis. Specif-
ically, ocular infection of mice previously vaccinated with
gK exacerbated corneal immunopathogenesis, while a
HSV-1 virus expressing two copies of the gK gene was sig-
nificantly more virulent than the wild-type virus [36,37,48].
Therefore, lack of a functional gK will potentially reduce
gK-associated immunopathogenesis, while preventing the
virus from infecting ganglionic neurons.
Our results are consistent with the widely accepted no-
tion that pre-existing HSV-1 exposure reduces the severity
or duration of HSV-2 acquisition [10]. Ideally, a live-
attenuated vaccine could be used for both prophylactic
and therapeutic purposes. Elicitation of adaptive immune
responses would confer substantial advantage in control-
ling HSV infections especially, if new ways are found to
boost vaccine-induced innate immune activation and sub-
sequent protective adaptive immune responses.
Materials and methods
Viruses
HSV-1 (F) gK-null virus has been described previously [40]
and was used as the vaccine virus. A schematic for the con-
struction of gK-null is shown in Figure 1. The virus was
grown in a gK-complementing VK302 cell line to high titers
and passaged once through Vero cells to eliminate carry-
over of gK containing particles. Cells were freeze-thawed
twice to release intracellular viruses and clarified by centri-
fugation to eliminate cell debris. Virus titers were deter-
mined on VK302 and Vero cells. The challenge viruses,
HSV-1 (McKrae) and HSV-2 (G) were grown to high titersand titrated in Vero cells. The viruses were assayed for viru-
lence in mice.
Mouse immunization
All animal studies were carried out after the appropriate ap-
provals were obtained from the Louisiana State University
Institutional Animal Care and Use Committee. Six week-
old female Balb/c mice (Charles River Laboratories Inter-
national, Inc., Wilmington, MA, USA) were used in this
study. Each mouse was identified with an ear tag (National
Band and Tag Company, KY, USA). Mice were divided into
two groups to receive either the vaccine or mock inocula-
tions. The animals were mildly anesthetized by inhalation
of 2-3% isoflurane and vaccinated intramuscularly with 106
PFU in 100 μl volume of the gK-null virus or with 100 μl of
uninfected Vero cell supernatant as sham control.
Challenge
Fourteen days after primary or mock-vaccination, the ani-
mals for challenge were anesthetized by inhalation of 2-3%
isoflurane and administered 2 mg Depo Provera (Upjohn,
Kalamazoo, MI) subcutaneously under the scruff. Twenty-
one days post vaccination (7 days after administration of
Depo-Provera) [42], animals in challenge groups (n = 10)
were anesthetized with 100 μl xylazine (14.3 mg/ml) and
ketamine (1.8 mg/ml) mixture and prepared for challenge.
The vaginas of anesthetized animals were swabbed with
sterile PBS-soaked Dacron applicators (Puritan, Guildford,
ME) to remove associated mucus. Ten microliters (106
PFU) of HSV-1 McKrae or HSV-2G was instilled in the
vaginal vault using a micropipette. The mice were held in
dorsal recumbency until they recovered from anesthesia.
All mice in challenge groups were examined daily for
14 days for signs of disease and death. Animals showing
severe neurological symptoms, e.g. ataxia and paralysis,
were humanely euthanized.
Polychromatic flow cytometric staining and analysis
Freshly excised spleens were lightly mashed and mechan-
ically separated using 100 μm nylon mesh cell strainers
(Fisher Scientific) in RPMI plus 10% FBS followed by
10 minutes in hypotonic ACK buffer to lyse red blood cells
(Invitrogen). Isolated splenocytes were subsequently ad-
justed to 107 cells/ml. One hundred microliter aliquots of
splenocyte suspension were incubated with appropriately
diluted concentrations of antibodies for 30 min at room
temperature. Cells were washed once with PBS and fixed
with 1X BD stabilizing fixative buffer (BD Biosciences) in
distilled water. Cells were kept protected from light at 4°C
and flow cytometric acquisition was completed within
24 h of staining. Polychromatic (7 parameters) flow cyto-
metric acquisition was performed on a LSR II Becton
Dickinson instrument having three lasers (488 nm blue
laser, 633 nm red laser and 407 nm violet laser) by using
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fluorochrome parameters. Single-stained controls for each
fluorochrome were used for setting flow cytometry com-
pensation. Monoclonal antibodies including anti-CD69
FITC (H1.2F3, BD Biosciences), FoxP3 PE (FJK-16s,
eBioscience), CD25 APC (3C7, BD Biosciences), CD4
APC-Cy7 (GK1.5, BD Biosciences) and CD8a Pacific Blue
(53–6.7, BD Biosciences) were used. FoxP3 staining was
performed by intracellular staining after performing sur-
face staining for all other monoclonal antibodies specified
above using the FoxP3 buffer set (Biosciences) and manu-
facturer’s protocol. At-least 50,000 events were collected
by gating on CD4+ T cells and these data were analyzed
using FlowJo software version 9.6 (TreeStar Inc.).
To test CD4+ and CD8+ T lymphocyte subsets for IFN-
γ and TNF-α production and response to recall antigens,
intracellular cytokine flow cytometry assay was employed.
Cells were stimulated with either HSV-1 gB (aa 161–176;
ATMYYKDVTVSQVWF), gD (aa 70–78; SLPITVYYA) or
gD (aa 278–286; ALLEDPVGT) peptides in the presence
of 0.5 μg/ml of anti-CD28 (37.51, BD Biosciences) and
anti-CD49d (9C10, BD Biosciences) monoclonal anti-
bodies as described previously [51]. Processed splenocytes
were resuspended at 106 cells/ml in complete RPMI-10
with 10% FCS, and stimulated with different HSV-1 pep-
tides as specified above at a final concentration of 1 μg/ml.
All peptides were synthesized at the LSU Protein Facility
(Dr. Ted Gauthier). Phorbol myristic acid (50 ng/ml,
Sigma) and ionomycin (1 μg/ml, Sigma) were used as posi-
tive controls for T cell activation. Negative controls had
no antigen or mitogen stimulation. Brefeldin A (10 μg/ml,
Sigma) was added to cultures after the first hour, followed
by a 6-hour incubation. Following stimulation, cells were
stained for cell surface markers with directly conjugated
monoclonal antibodies to CD4 APC-Cy7 and CD8a pacific
blue for 30 min at room temperature and washed with
dPBS/BSA wash buffer. Cells were then fixed and perme-
abilized by using Cytofix/Cytoperm (BD Biosciences),
washed twice in Perm Buffer (BD Biosciences), and stained
with intracellular monoclonal antibodies against IFN-γ PE
(XMG1.2, BD Biosciences) and TNF-α APC (MP6-XT22,
BD Biosciences) were added to cells and incubated at
room temperature for 30 min. Single color and isotype-
matched control antibodies were used to confirm staining
specificity. After washing, cells were resuspended in 1%
paraformaldehyde in PBS and stored in the dark at 4°C.
Data were acquired within 24 h of staining using a LSR II
instrument (BD Immunocytometry System) and FACS-
Diva software (BD Immunocytometry System). For each
sample, 50,000 events were collected by gating on CD4+
T cells. Data analysis was performed using FlowJo soft-
ware. Cells were gated on singlets followed by CD4+ and
CD8+ T cell subsets. Gated CD4+ and CD8+ T cells were
further analyzed for its cytokine production. Positivecytokine responses were determined based on the percent-
age of cytokine responses obtained above background re-
sponses (unstimulated control) in each experiment. The
cut off values were determined based on the cytokine re-
sponses obtained from mock-infected mice.
Additional file
Additional file 1: Figure S1. Intracellular cytokine flow cytometry for
IFN-γ responses from a representative vaccinated mouse. Splenocytes
were left unstimulated (media control) or stimulated for 6 h with
different gB and gD peptides. Cells were gated first on singlets followed
by lymphocytes and CD4 and CD8 population. The percentages of IFN-γ
positive cells are shown in each quadrant.
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